Verified Nov 2026
Other
·
Hampton, New Jersey
·
Since 2007
Ikaria, Inc. is a critical care company headquartered in Hampton, New Jersey, United States, founded in 2007. It is estimated to have 50 to 100 employees and revenue in the $1 to 5 billion range, and it is now part of Mallinckrodt Pharmaceuticals following Mallinckrodt's 2015 acquisition. The company developed inhaled nitric oxide therapy, including its INOmax product for hypoxic respiratory failure in term and near-term neonates, and serves the medical sector.
Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. at a glance
Revenue
$1-5B
Est. band
Employees
50-100
Founded
2007
Headquarters
Hampton, New Jersey
Import activity
1408
Industries
Automotive
Electric Vehicles
Medical
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
1408
Named foreign suppliers
41
Top origins
Italy · India · Netherlands · Canada
Shared foreign counterparties do not establish that these companies buy from Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals..
What this tells a buyer
Mallinckrodt announced in November 2025 that it had completed the spin-off of Par Health and introduced Keenova Therapeutics, and in November 2026 a court eliminated a $9.5 million patent award the company had won.
The company's flagship product is INOmax, an inhaled nitric oxide vasodilator delivered through a specialized device for neonatal patients in intensive care.
Ikaria is privately held as part of Mallinckrodt Pharmaceuticals, which acquired it in April 2015 for approximately $2.3 billion.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Ikaria, Inc. is a critical care company headquartered in Hampton, New Jersey, United States, founded in 2007. It is estimated to have 50 to 100 employees and revenue in the $1 to 5 billion range, and it is now part of Mallinckrodt Pharmaceuticals following Mallinckrodt's 2015 acquisition. The company developed inhaled nitric oxide therapy, including its INOmax product for hypoxic respiratory failure in term and near-term neonates, and serves the medical sector.
At a glance
Attribute | Detail |
|---|---|
Founded | 2007 |
Headquarters | Hampton, New Jersey |
Employees | 50-100 |
Revenue | $1-5B (estimated) |
What Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. makes
The company's flagship product is INOmax, an inhaled nitric oxide vasodilator delivered through a specialized device for neonatal patients in intensive care.
Trade and customs footprint
Mallinckrodt announced in November 2025 that it had completed the spin-off of Par Health and introduced Keenova Therapeutics, and in November 2026 a court eliminated a $9.5 million patent award the company had won. US customs bill-of-lading records list 1408 inbound shipments across 41 foreign suppliers, with top origins including Italy · India · Netherlands · Canada.
Latest developments
2026-11-05 — Mallinckrodt’s $9.5 Million Award on Patent Win Wiped by Judge (bloomberglaw.com)
2026-11-04 — Mallinckrodt Loses $9.5M Award, Wins Delay In Airgas Drug - Law360 (law360.com)
2025-11-10 — Mallinckrodt Completes Spin-Off of Par Health, Introduces Keenova Therapeutics | Keenova (gcs-web.com)
2025-11-10 — Mallinckrodt Reports Third Quarter 2025 Financial Results | Keenova (mallinckrodt.com)
2025-08-20 — Swooped - Pharmaceutical Operator I at IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. (swooped.co)
2025-08-15 — Swooped - Senior Technical Product Specialist - Medical Device at IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals. (swooped.co)
Facilities
Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. is headquartered in Hampton, New Jersey. Public sources also reference these locations:
Clinton, NJ — life-sciences-usa.com
Seattle, WA — life-sciences-usa.com
Company details
Ikaria is privately held as part of Mallinckrodt Pharmaceuticals, which acquired it in April 2015 for approximately $2.3 billion. Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. was founded in 2007, has an estimated 50-100 employees, and is headquartered in Hampton, New Jersey.
Frequently asked questions
What does Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. do?
Ikaria, Inc. is a critical care company headquartered in Hampton, New Jersey, United States, founded in 2007. It is estimated to have 50 to 100 employees and revenue in the $1 to 5 billion range, and it is now part of Mallinckrodt Pharmaceuticals following Mallinckrodt's 2015 acquisition. The company developed inhaled nitric oxide therapy, including its INOmax product for hypoxic respiratory failure in term and near-term neonates, and serves the medical sector.
Where is Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. headquartered?
Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. is headquartered in Hampton, New Jersey (53 Frontage Rd, Hampton, New Jersey, 08827).
When was Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. founded?
Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. was founded in 2007.
How big is Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals.?
Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. has an estimated 50-100 employees, with revenue in the $1-5B range (estimated).
Does Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals. import from overseas suppliers?
US customs bill-of-lading records show 1408 inbound shipments for Ikaria, Inc. - now a part of Mallinckrodt Pharmaceuticals., with top origins including Italy · India · Netherlands · Canada.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.